DeepMed Research

Bausch & Lomb Incorporated

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Established: 1992-10-08

Employees: -

Market Cap: -

Website

Clinical Trials

A Study to Evaluate the Clinical Performance of a Novel Multipurpose Solution

Not Applicable

Completed

Conditions: Ocular Discomfort

Interventions: Device: Bausch & Lomb Multi-Purpose Solution
Device: Ciba's Multi-Purpose Solution

First Posted Date: 2009-12-03

Last Posted Date: 2011-08-15

Lead Sponsor: Bausch & Lomb Incorporated

Target Recruit Count: 312

Registration Number: NCT01024751

Locations: 🇺🇸
Bausch & Lomb, Rochester, New York, United States

Loteprednol Etabonate Versus Vehicle for the Treatment of Inflammation and Pain Following Cataract Surgery

Phase 3

Completed

Conditions: Inflammation
Pain

Interventions: Drug: Vehicle of Loteprednol Etabonate
Drug: Loteprednol Etabonate

First Posted Date: 2009-11-10

Last Posted Date: 2012-01-09

Lead Sponsor: Bausch & Lomb Incorporated

Target Recruit Count: 406

Registration Number: NCT01010633

Locations: 🇺🇸
Bausch & Lomb, Inc., Rochester, New York, United States

Performance Evaluation of Contact Lenses Among a Population of Adapted Contact Lens Wearers

Not Applicable

Completed

Conditions: Vision Disorders

Interventions: Device: SofLens59 contact lens
Device: PureVision Multi-Focal contact lenses

First Posted Date: 2009-09-28

Last Posted Date: 2015-03-24

Lead Sponsor: Bausch & Lomb Incorporated

Target Recruit Count: 272

Registration Number: NCT00985231

Locations: 🇺🇸
Bausch & Lomb, Rochester, New York, United States

Efficacy of Besifloxacin Ophthalmic Suspension in the Treatment of Bacterial Conjunctivitis

Phase 2

Completed

Conditions: Bacterial Conjunctivitis

Interventions: Drug: Vehicle (Placebo)
Drug: Besifloxacin

First Posted Date: 2009-09-09

Last Posted Date: 2012-03-29

Lead Sponsor: Bausch & Lomb Incorporated

Target Recruit Count: 474

Registration Number: NCT00972777

Locations: 🇺🇸
Bausch & Lomb Incorporated, Rochester, New York, United States

Concentration of Besifloxacin, Gatifloxacin, and Moxifloxacin in Human Conjunctiva After Topical Instillation

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Moxifloxacin
Drug: Besifloxacin
Drug: Gatifloxacin

First Posted Date: 2009-05-21

Last Posted Date: 2011-12-09

Lead Sponsor: Bausch & Lomb Incorporated

Target Recruit Count: 119

Registration Number: NCT00905762

Locations: 🇺🇸
Bausch & Lomb Incorporated, Rochester, New York, United States

Indomethacin Eyedrops Compared With Ketorolac Eyedrops for Ocular Inflammation Following Cataract Surgery

Phase 4

Completed

Conditions: Cataract
Inflammation

Interventions: Drug: Indomethacin ophthalmic solution
Drug: Ketorolac Ophthalmic Solution

First Posted Date: 2009-05-20

Last Posted Date: 2012-08-13

Lead Sponsor: Bausch & Lomb Incorporated

Target Recruit Count: 120

Registration Number: NCT00904904

Locations: 🇩🇪
Bausch & Lomb, Berlin, Germany

Evaluation of BOL-303242-X Versus Vehicle for the Treatment of Inflammation Following Cataract Surgery

Phase 2

Completed

Conditions: Cataract
Inflammation

Interventions: Drug: Vehicle for BOL-303242-X
Drug: BOL-303242-X

First Posted Date: 2009-05-20

Last Posted Date: 2020-09-22

Lead Sponsor: Bausch & Lomb Incorporated

Target Recruit Count: 415

Registration Number: NCT00905450

Locations: 🇺🇸
Bausch & Lomb, Rochester, New York, United States

One-Day Dispensing Clinical Evaluation of SofLens Daily Disposable Lenses Compared to a Marketed 1 Day Contact Lens

Not Applicable

Completed

Conditions: Myopia

Interventions: Device: SofLens Daily Disposable
Device: Marketed 1 Day Contact Lens

First Posted Date: 2009-05-15

Last Posted Date: 2015-03-02

Lead Sponsor: Bausch & Lomb Incorporated

Target Recruit Count: 28

Registration Number: NCT00902850

Locations: 🇺🇸
Bausch & Lomb Research Clinic, Rochester, New York, United States

Study of T-PRED(TM) Compared to Pred Forte(R) II

Phase 3

Completed

Conditions: Cataract

Interventions: Drug: T-Pred
Drug: Pred Forte

First Posted Date: 2009-03-02

Last Posted Date: 2020-10-20

Lead Sponsor: Bausch & Lomb Incorporated

Target Recruit Count: 172

Registration Number: NCT00854061

Locations: 🇺🇸
ISTA Pharmaceuticals, Inc., Irvine, California, United States

Efficacy Study of Bromfenac Ophthalmic Solution in Patients Undergoing Cataract Surgery

Phase 3

Completed

Conditions: Pain
Inflammation

Interventions: Drug: Placebo Comparator
Drug: Bromfenac Ophthalmic Solution

First Posted Date: 2009-03-02

Last Posted Date: 2013-01-25

Lead Sponsor: Bausch & Lomb Incorporated

Target Recruit Count: 299

Registration Number: NCT00853970

Locations: 🇺🇸
ISTA Pharmaceuticals, Inc., Irvine, California, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy